Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fortrea Holdings Inc. (FTRE – Research ...

The company's backlog, which consists of anticipated future revenue from business awards, stood at $7.7 billion as of ...

Diamond Hill Small-Mid Cap Fund portfolio trailed the Russell 2500 Index in Q4 and for the full year. Click here to read the ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after ...

In a report released today, Max Smock from William Blair maintained a Hold rating on Fortrea Holdings Inc. (FTRE – Research Report). The ...

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -50% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...